We hypothesized that abnormal oxidative stress in chronic heart failure (CHF) could be related to endothelial damage and platelet activation, and that the vasodilating β-blocker carvedilol would have beneficial effects on these processes compared with a selective non-vasodilating cardioselective β-blocker, bisoprolol. We therefore assessed the effects of introducing carvedilol and bisoprolol in a prospective manner on indices of oxidative stress [lipid hydroperoxides (LHP)], endothelial damage [von Willebrand factor (vWf)], platelet activation (soluble P-selectin) and coagulation (fibrinogen) and their inter-relationships in stable outpatients with CHF in sinus rhythm. We recruited 46 patients [23 male; age 64±13 years (mean±S.D.); range 38–85 years] with CHF. Baseline levels of serum LHP (P<0.002), plasma vWf (P<0.001) and soluble P-selectin (P=0.02), but not fibrinogen (P=0.16), were higher in CHF patients compared with 22 age- and sex-matched healthy controls. After treatment for 2 months, systolic blood pressure fell in both arms of the study (both P<0.01), but there were no statistically significant (defined as P<0.01) decreases in LHP, vWf, fibrinogen or soluble P-selectin levels with either carvedilol or bisoprolol. In conclusion, patients with CHF have increased levels of plasma LHP and vWf, indicating increased oxidative stress and endothelial damage respectively. Contrary to the proposed antioxidative effects of carvedilol, initiating and titrating such therapy did not result in a reduction in levels of LHP in CHF.
Skip Nav Destination
Article navigation
October 2003
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
Research Article|
October 01 2003
Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for β-blocker selection
Bernard S. P. CHIN;
Bernard S. P. CHIN
1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, U.K.
Search for other works by this author on:
Christopher R. GIBBS;
Christopher R. GIBBS
1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, U.K.
Search for other works by this author on:
Andrew D. BLANN;
Andrew D. BLANN
1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, U.K.
Search for other works by this author on:
Gregory Y. H. LIP
1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, U.K.
Correspondence: Professor G. Y. H. Lip (e-mail g.y.h.lip@bham.ac.uk).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
May 12 2003
Revision Received:
May 30 2003
Accepted:
July 03 2003
Accepted Manuscript online:
July 03 2003
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2003 The Biochemical Society
2003
Clin Sci (Lond) (2003) 105 (4): 507–512.
Article history
Received:
May 12 2003
Revision Received:
May 30 2003
Accepted:
July 03 2003
Accepted Manuscript online:
July 03 2003
Citation
Bernard S. P. CHIN, Christopher R. GIBBS, Andrew D. BLANN, Gregory Y. H. LIP; Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for β-blocker selection. Clin Sci (Lond) 1 October 2003; 105 (4): 507–512. doi: https://doi.org/10.1042/CS20030172
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.